Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Plaque, Atherosclerotic | 83 | 2024 | 1532 | 12.330 |
Why?
|
Coronary Artery Disease | 113 | 2024 | 6403 | 7.640 |
Why?
|
Coronary Vessels | 69 | 2024 | 3096 | 6.350 |
Why?
|
Coronary Angiography | 80 | 2024 | 4471 | 4.220 |
Why?
|
Endothelium, Vascular | 37 | 2023 | 4431 | 4.050 |
Why?
|
Coronary Circulation | 31 | 2024 | 1569 | 4.010 |
Why?
|
Myocardial Ischemia | 42 | 2024 | 2113 | 3.470 |
Why?
|
Stress, Mechanical | 31 | 2023 | 1674 | 3.460 |
Why?
|
Shear Strength | 7 | 2019 | 160 | 2.410 |
Why?
|
Angina Pectoris | 29 | 2023 | 959 | 2.280 |
Why?
|
Electrocardiography, Ambulatory | 35 | 2017 | 578 | 2.190 |
Why?
|
Hemodynamics | 22 | 2024 | 4160 | 1.820 |
Why?
|
Angina, Unstable | 22 | 2022 | 888 | 1.590 |
Why?
|
Ultrasonography, Interventional | 21 | 2024 | 1496 | 1.380 |
Why?
|
Angioplasty, Balloon, Coronary | 16 | 2021 | 1725 | 1.350 |
Why?
|
Coronary Restenosis | 6 | 2019 | 396 | 1.310 |
Why?
|
Coronary Disease | 34 | 2020 | 5914 | 1.280 |
Why?
|
Acute Coronary Syndrome | 16 | 2024 | 2190 | 1.280 |
Why?
|
Myocardial Revascularization | 9 | 2022 | 790 | 1.220 |
Why?
|
Coronary Stenosis | 10 | 2021 | 794 | 1.150 |
Why?
|
Stents | 10 | 2021 | 3179 | 1.150 |
Why?
|
Acetanilides | 5 | 2013 | 169 | 1.130 |
Why?
|
Disease Progression | 47 | 2024 | 13510 | 1.110 |
Why?
|
Atherosclerosis | 13 | 2023 | 3407 | 1.020 |
Why?
|
Exercise Test | 27 | 2017 | 2127 | 0.950 |
Why?
|
Predictive Value of Tests | 44 | 2024 | 15266 | 0.950 |
Why?
|
Arrhythmias, Cardiac | 9 | 2023 | 2244 | 0.920 |
Why?
|
Myocardial Infarction | 65 | 2024 | 11461 | 0.920 |
Why?
|
Models, Cardiovascular | 9 | 2020 | 981 | 0.900 |
Why?
|
Neointima | 4 | 2016 | 133 | 0.870 |
Why?
|
Nifedipine | 15 | 2000 | 221 | 0.840 |
Why?
|
Regional Blood Flow | 6 | 2018 | 1496 | 0.770 |
Why?
|
Piperazines | 5 | 2013 | 2523 | 0.690 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2023 | 3246 | 0.640 |
Why?
|
Electrodes, Implanted | 1 | 2023 | 840 | 0.630 |
Why?
|
Humans | 275 | 2024 | 761596 | 0.630 |
Why?
|
Stress, Physiological | 6 | 2017 | 1403 | 0.610 |
Why?
|
Drug-Eluting Stents | 4 | 2016 | 681 | 0.580 |
Why?
|
Imaging, Three-Dimensional | 8 | 2020 | 4062 | 0.570 |
Why?
|
Microcirculation | 3 | 2018 | 1272 | 0.560 |
Why?
|
Tomography, Optical Coherence | 10 | 2024 | 2917 | 0.550 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2020 | 323 | 0.540 |
Why?
|
Heptanoic Acids | 4 | 2007 | 344 | 0.520 |
Why?
|
Rupture, Spontaneous | 6 | 2024 | 362 | 0.510 |
Why?
|
Arteries | 4 | 2021 | 1123 | 0.510 |
Why?
|
Vasodilator Agents | 6 | 2006 | 973 | 0.490 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 5 | 2024 | 1222 | 0.480 |
Why?
|
Heart Rate | 23 | 2011 | 4195 | 0.460 |
Why?
|
Vehicle Emissions | 4 | 2007 | 656 | 0.440 |
Why?
|
Middle Aged | 144 | 2024 | 220921 | 0.440 |
Why?
|
Male | 163 | 2024 | 360846 | 0.430 |
Why?
|
Risk Factors | 59 | 2024 | 74213 | 0.430 |
Why?
|
Hyperplasia | 1 | 2016 | 1152 | 0.430 |
Why?
|
Adrenergic beta-Antagonists | 14 | 2013 | 1241 | 0.430 |
Why?
|
Electrocardiography | 34 | 2011 | 6377 | 0.420 |
Why?
|
Procollagen | 1 | 2013 | 187 | 0.410 |
Why?
|
Endothelium | 1 | 2015 | 765 | 0.410 |
Why?
|
Registries | 24 | 2024 | 8225 | 0.400 |
Why?
|
Diabetic Angiopathies | 4 | 2018 | 803 | 0.400 |
Why?
|
Matrix Metalloproteinases | 2 | 2013 | 393 | 0.390 |
Why?
|
Cholesterol, LDL | 10 | 2019 | 2382 | 0.390 |
Why?
|
Sodium Channel Blockers | 1 | 2013 | 173 | 0.390 |
Why?
|
Aged | 108 | 2024 | 169310 | 0.390 |
Why?
|
Pyrroles | 4 | 2007 | 1125 | 0.380 |
Why?
|
Amlodipine | 4 | 2006 | 84 | 0.370 |
Why?
|
Aviation | 1 | 2011 | 49 | 0.370 |
Why?
|
Sodium Channels | 1 | 2013 | 339 | 0.370 |
Why?
|
Female | 152 | 2024 | 392705 | 0.370 |
Why?
|
Computer Simulation | 6 | 2016 | 6241 | 0.350 |
Why?
|
Enzyme Inhibitors | 2 | 2011 | 3713 | 0.350 |
Why?
|
Allopurinol | 1 | 2011 | 198 | 0.340 |
Why?
|
Collagen Type I | 1 | 2013 | 616 | 0.340 |
Why?
|
Air Pollution | 7 | 2010 | 2359 | 0.340 |
Why?
|
Risk Assessment | 25 | 2024 | 23996 | 0.340 |
Why?
|
Stress, Psychological | 9 | 2022 | 4481 | 0.330 |
Why?
|
Coronary Thrombosis | 3 | 2020 | 440 | 0.330 |
Why?
|
Anticholesteremic Agents | 4 | 2007 | 966 | 0.330 |
Why?
|
Blood Flow Velocity | 8 | 2015 | 1371 | 0.330 |
Why?
|
Prospective Studies | 37 | 2024 | 54423 | 0.330 |
Why?
|
Diabetes Mellitus, Experimental | 6 | 2021 | 1119 | 0.320 |
Why?
|
Ischemia | 6 | 2022 | 1884 | 0.320 |
Why?
|
Time Factors | 44 | 2024 | 39969 | 0.310 |
Why?
|
Metals | 4 | 2016 | 719 | 0.310 |
Why?
|
Cardiomegaly | 1 | 2011 | 590 | 0.310 |
Why?
|
Diltiazem | 6 | 2005 | 131 | 0.300 |
Why?
|
Air Pollutants | 10 | 2014 | 2896 | 0.300 |
Why?
|
Treatment Outcome | 29 | 2022 | 64685 | 0.300 |
Why?
|
Calcium Channel Blockers | 7 | 2013 | 694 | 0.300 |
Why?
|
Oxidative Stress | 4 | 2014 | 3113 | 0.290 |
Why?
|
Extracellular Matrix | 2 | 2014 | 1726 | 0.280 |
Why?
|
Motor Vehicles | 2 | 2009 | 282 | 0.280 |
Why?
|
Physical Exertion | 7 | 1996 | 667 | 0.280 |
Why?
|
Calcium Signaling | 1 | 2011 | 733 | 0.280 |
Why?
|
Valine | 1 | 2008 | 408 | 0.270 |
Why?
|
Circadian Rhythm | 11 | 1997 | 2576 | 0.270 |
Why?
|
Antioxidants | 2 | 2005 | 1668 | 0.270 |
Why?
|
Hypertension | 8 | 2021 | 8540 | 0.260 |
Why?
|
Calcinosis | 2 | 2021 | 1469 | 0.260 |
Why?
|
Aortic Valve | 2 | 2021 | 1955 | 0.260 |
Why?
|
Particulate Matter | 6 | 2010 | 2605 | 0.260 |
Why?
|
Simvastatin | 1 | 2008 | 346 | 0.260 |
Why?
|
Ventricular Remodeling | 2 | 2010 | 1267 | 0.260 |
Why?
|
Diabetes Mellitus | 5 | 2018 | 5841 | 0.250 |
Why?
|
Aortic Valve Stenosis | 3 | 2021 | 2001 | 0.250 |
Why?
|
Bioprosthesis | 1 | 2009 | 591 | 0.250 |
Why?
|
Prognosis | 34 | 2024 | 29629 | 0.240 |
Why?
|
Antihypertensive Agents | 2 | 2019 | 2024 | 0.240 |
Why?
|
Blood Pressure | 14 | 2019 | 8481 | 0.240 |
Why?
|
Cholesterol, HDL | 6 | 2024 | 1814 | 0.240 |
Why?
|
Tomography, X-Ray Computed | 6 | 2023 | 20568 | 0.240 |
Why?
|
Cardiac Imaging Techniques | 2 | 2017 | 267 | 0.230 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2006 | 577 | 0.230 |
Why?
|
Ascorbic Acid | 2 | 2005 | 655 | 0.230 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2007 | 705 | 0.230 |
Why?
|
Carbon | 3 | 2009 | 666 | 0.220 |
Why?
|
Propranolol | 5 | 1993 | 489 | 0.220 |
Why?
|
Swine | 8 | 2020 | 5915 | 0.220 |
Why?
|
Vitamin E | 2 | 2005 | 872 | 0.210 |
Why?
|
Atenolol | 4 | 2000 | 99 | 0.210 |
Why?
|
Double-Blind Method | 19 | 2017 | 12341 | 0.210 |
Why?
|
Occupational Diseases | 1 | 2011 | 1490 | 0.210 |
Why?
|
Benchmarking | 2 | 2019 | 1045 | 0.210 |
Why?
|
Blood Glucose | 3 | 2024 | 6391 | 0.210 |
Why?
|
Myocytes, Cardiac | 1 | 2011 | 1668 | 0.200 |
Why?
|
Tetrazoles | 1 | 2008 | 909 | 0.200 |
Why?
|
Carotid Artery Diseases | 2 | 2021 | 877 | 0.200 |
Why?
|
Heart Valve Prosthesis | 2 | 2009 | 1462 | 0.200 |
Why?
|
Cardiovascular Agents | 5 | 2017 | 840 | 0.200 |
Why?
|
Ultrasonography | 6 | 2016 | 5971 | 0.200 |
Why?
|
Random Allocation | 12 | 2018 | 2395 | 0.200 |
Why?
|
Stroke | 2 | 2023 | 9758 | 0.190 |
Why?
|
Heart | 5 | 2023 | 4404 | 0.190 |
Why?
|
Food, Formulated | 1 | 2002 | 101 | 0.190 |
Why?
|
Japan | 2 | 2016 | 1378 | 0.190 |
Why?
|
Carotid Arteries | 3 | 2016 | 941 | 0.190 |
Why?
|
Vasodilation | 4 | 2015 | 962 | 0.190 |
Why?
|
Severity of Illness Index | 15 | 2024 | 15843 | 0.180 |
Why?
|
Syndrome | 5 | 2021 | 3267 | 0.180 |
Why?
|
Death, Sudden | 5 | 1990 | 301 | 0.180 |
Why?
|
Brachial Artery | 3 | 2015 | 366 | 0.180 |
Why?
|
Membrane Glycoproteins | 1 | 2011 | 3701 | 0.180 |
Why?
|
Drug Therapy, Combination | 15 | 2015 | 6312 | 0.180 |
Why?
|
Dyslipidemias | 2 | 2019 | 868 | 0.180 |
Why?
|
Coronary Vasospasm | 4 | 1983 | 81 | 0.170 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2015 | 2751 | 0.170 |
Why?
|
Fibrinolytic Agents | 4 | 2006 | 2084 | 0.170 |
Why?
|
C-Reactive Protein | 5 | 2010 | 3826 | 0.170 |
Why?
|
Cardiovascular Diseases | 9 | 2007 | 15502 | 0.170 |
Why?
|
Prosthesis Failure | 2 | 2019 | 1204 | 0.170 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2020 | 112 | 0.170 |
Why?
|
Inflammation | 6 | 2022 | 10774 | 0.170 |
Why?
|
Nitroglycerin | 5 | 2006 | 329 | 0.160 |
Why?
|
Prosthesis Design | 3 | 2019 | 2115 | 0.160 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2009 | 1553 | 0.160 |
Why?
|
Hypercholesterolemia | 3 | 2021 | 1141 | 0.160 |
Why?
|
Cardiotonic Agents | 1 | 2002 | 539 | 0.160 |
Why?
|
Animals | 21 | 2021 | 168475 | 0.150 |
Why?
|
Lipids | 5 | 2022 | 3341 | 0.150 |
Why?
|
Thrombolytic Therapy | 6 | 2002 | 2064 | 0.150 |
Why?
|
Triglycerides | 5 | 2020 | 2461 | 0.150 |
Why?
|
Arginine | 1 | 2002 | 934 | 0.150 |
Why?
|
Receptors, LDL | 1 | 2020 | 488 | 0.150 |
Why?
|
Nadolol | 2 | 1994 | 29 | 0.150 |
Why?
|
Activities of Daily Living | 3 | 1999 | 2421 | 0.140 |
Why?
|
Lipoproteins, LDL | 2 | 2014 | 642 | 0.140 |
Why?
|
Vascular Resistance | 2 | 2013 | 930 | 0.140 |
Why?
|
Pilot Projects | 11 | 2017 | 8633 | 0.140 |
Why?
|
Sus scrofa | 3 | 2021 | 428 | 0.140 |
Why?
|
Cross-Over Studies | 4 | 2017 | 2079 | 0.140 |
Why?
|
Europe | 3 | 2018 | 3420 | 0.140 |
Why?
|
Sirolimus | 2 | 2016 | 1533 | 0.140 |
Why?
|
Lipid Metabolism | 1 | 2005 | 1902 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 12149 | 0.130 |
Why?
|
Cheyne-Stokes Respiration | 1 | 2016 | 38 | 0.130 |
Why?
|
Coronary Artery Bypass | 7 | 2001 | 2188 | 0.130 |
Why?
|
Arousal | 3 | 1999 | 1166 | 0.130 |
Why?
|
Telemetry | 1 | 2017 | 199 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2020 | 1246 | 0.130 |
Why?
|
Hyperglycemia | 1 | 2024 | 1376 | 0.130 |
Why?
|
Follow-Up Studies | 20 | 2018 | 39106 | 0.130 |
Why?
|
Sleep Apnea, Central | 1 | 2016 | 88 | 0.120 |
Why?
|
Mechanotransduction, Cellular | 1 | 2019 | 529 | 0.120 |
Why?
|
Indocyanine Green | 1 | 2016 | 233 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2019 | 10212 | 0.120 |
Why?
|
Hemorheology | 2 | 2007 | 144 | 0.120 |
Why?
|
Spectroscopy, Near-Infrared | 2 | 2017 | 740 | 0.120 |
Why?
|
Angina Pectoris, Variant | 5 | 2002 | 53 | 0.110 |
Why?
|
Thrombophilia | 2 | 2015 | 305 | 0.110 |
Why?
|
Pravastatin | 3 | 2015 | 392 | 0.110 |
Why?
|
Heart Conduction System | 3 | 2009 | 1007 | 0.110 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 2691 | 0.110 |
Why?
|
Rest | 2 | 1997 | 918 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 1516 | 0.110 |
Why?
|
Mental Processes | 1 | 1994 | 244 | 0.110 |
Why?
|
Hyperlipidemias | 3 | 2015 | 771 | 0.110 |
Why?
|
Logistic Models | 9 | 2016 | 13255 | 0.110 |
Why?
|
Hypolipidemic Agents | 3 | 2005 | 609 | 0.110 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2015 | 284 | 0.100 |
Why?
|
Adult | 37 | 2020 | 221210 | 0.100 |
Why?
|
Galvanic Skin Response | 1 | 1994 | 358 | 0.100 |
Why?
|
Muscle, Smooth, Vascular | 2 | 2013 | 1492 | 0.100 |
Why?
|
Aged, 80 and over | 18 | 2021 | 58984 | 0.100 |
Why?
|
NF-kappa B | 1 | 2020 | 2490 | 0.100 |
Why?
|
Creatine Kinase | 10 | 1989 | 685 | 0.100 |
Why?
|
Blood Volume | 1 | 2013 | 547 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2016 | 1186 | 0.090 |
Why?
|
Life Support Systems | 1 | 2010 | 11 | 0.090 |
Why?
|
Cathepsin K | 1 | 2011 | 65 | 0.090 |
Why?
|
Diastole | 4 | 2017 | 782 | 0.090 |
Why?
|
Ventricular Dysfunction, Left | 2 | 1999 | 2118 | 0.090 |
Why?
|
Pyridines | 4 | 1983 | 2875 | 0.090 |
Why?
|
Particle Size | 5 | 2009 | 1648 | 0.090 |
Why?
|
Ticlopidine | 1 | 2015 | 730 | 0.090 |
Why?
|
Enzyme Induction | 1 | 2011 | 452 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2872 | 0.090 |
Why?
|
Constriction, Pathologic | 3 | 2023 | 1096 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2010 | 10766 | 0.090 |
Why?
|
Hypoxia, Brain | 1 | 2010 | 138 | 0.090 |
Why?
|
Treatment Failure | 3 | 2002 | 2643 | 0.090 |
Why?
|
Clinical Trials as Topic | 11 | 2013 | 8002 | 0.090 |
Why?
|
DNA Damage | 1 | 2020 | 2449 | 0.090 |
Why?
|
Fibrosis | 3 | 2018 | 2049 | 0.090 |
Why?
|
Cathepsins | 1 | 2011 | 241 | 0.090 |
Why?
|
Dental Care for Disabled | 1 | 1989 | 22 | 0.080 |
Why?
|
Anticoagulants | 2 | 2003 | 4812 | 0.080 |
Why?
|
Vascular Patency | 2 | 2003 | 911 | 0.080 |
Why?
|
Sex Factors | 10 | 2020 | 10554 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2578 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2021 | 2242 | 0.080 |
Why?
|
Uric Acid | 1 | 2015 | 807 | 0.080 |
Why?
|
Cardiology | 1 | 2020 | 1656 | 0.080 |
Why?
|
Nitrates | 3 | 2006 | 263 | 0.080 |
Why?
|
Multivariate Analysis | 7 | 2018 | 12059 | 0.080 |
Why?
|
Environmental Exposure | 3 | 2014 | 4485 | 0.080 |
Why?
|
Glucuronidase | 1 | 2010 | 202 | 0.080 |
Why?
|
Patient Selection | 2 | 2010 | 4244 | 0.080 |
Why?
|
Reproducibility of Results | 7 | 2024 | 20100 | 0.080 |
Why?
|
Heparin | 3 | 2006 | 1634 | 0.080 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 699 | 0.080 |
Why?
|
Monitoring, Physiologic | 4 | 2010 | 1779 | 0.080 |
Why?
|
Metoprolol | 1 | 1989 | 90 | 0.080 |
Why?
|
Tunica Intima | 1 | 2011 | 459 | 0.080 |
Why?
|
Workload | 2 | 2004 | 844 | 0.080 |
Why?
|
Platelet Aggregation | 2 | 1989 | 771 | 0.080 |
Why?
|
Calcium | 1 | 2021 | 5722 | 0.080 |
Why?
|
Radionuclide Imaging | 3 | 2011 | 1972 | 0.080 |
Why?
|
Fluorescent Dyes | 1 | 2016 | 1903 | 0.080 |
Why?
|
Hydrodynamics | 2 | 2020 | 168 | 0.070 |
Why?
|
Arteriosclerosis | 3 | 2003 | 1055 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2016 | 9001 | 0.070 |
Why?
|
Calcium Channels | 1 | 2011 | 620 | 0.070 |
Why?
|
Linear Models | 4 | 2018 | 5872 | 0.070 |
Why?
|
Maximum Allowable Concentration | 1 | 2007 | 63 | 0.070 |
Why?
|
Death, Sudden, Cardiac | 4 | 2020 | 1555 | 0.070 |
Why?
|
Ventricular Function, Left | 3 | 2017 | 3879 | 0.070 |
Why?
|
Disease Models, Animal | 4 | 2016 | 18255 | 0.070 |
Why?
|
Aspirin | 2 | 2015 | 3133 | 0.070 |
Why?
|
Nitric Oxide | 2 | 2007 | 2136 | 0.070 |
Why?
|
Counterpulsation | 1 | 2006 | 16 | 0.070 |
Why?
|
Recurrence | 11 | 2019 | 8466 | 0.070 |
Why?
|
Autonomic Nervous System | 2 | 2006 | 703 | 0.070 |
Why?
|
Medical Errors | 2 | 2005 | 1263 | 0.070 |
Why?
|
Helminth Proteins | 1 | 2007 | 173 | 0.070 |
Why?
|
Cholesterol | 2 | 1995 | 2905 | 0.070 |
Why?
|
Republic of Korea | 2 | 2018 | 590 | 0.070 |
Why?
|
Dietary Fats | 2 | 2011 | 1995 | 0.070 |
Why?
|
Thrombosis | 2 | 2019 | 2942 | 0.070 |
Why?
|
Retrospective Studies | 12 | 2023 | 80647 | 0.070 |
Why?
|
Plasminogen Activators | 2 | 1997 | 199 | 0.070 |
Why?
|
Case-Control Studies | 6 | 2022 | 22176 | 0.070 |
Why?
|
Mechanoreceptors | 1 | 2007 | 188 | 0.060 |
Why?
|
Medical History Taking | 1 | 1989 | 774 | 0.060 |
Why?
|
Elastic Tissue | 1 | 2005 | 66 | 0.060 |
Why?
|
Hypothermia, Induced | 1 | 2010 | 753 | 0.060 |
Why?
|
Ventricular Dysfunction | 1 | 2006 | 144 | 0.060 |
Why?
|
Endocarditis, Bacterial | 1 | 1989 | 436 | 0.060 |
Why?
|
Therapeutics | 1 | 2005 | 113 | 0.060 |
Why?
|
Odds Ratio | 2 | 2015 | 9647 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9420 | 0.060 |
Why?
|
Isoenzymes | 10 | 1989 | 1687 | 0.060 |
Why?
|
North America | 2 | 2018 | 1276 | 0.060 |
Why?
|
Vasomotor System | 1 | 2005 | 207 | 0.060 |
Why?
|
Exercise Tolerance | 2 | 2017 | 836 | 0.060 |
Why?
|
Cohort Studies | 9 | 2022 | 41495 | 0.060 |
Why?
|
Brazil | 2 | 2018 | 1230 | 0.060 |
Why?
|
Air Pollutants, Occupational | 1 | 2006 | 407 | 0.060 |
Why?
|
Personnel Staffing and Scheduling | 2 | 2004 | 495 | 0.060 |
Why?
|
Automobile Driving | 1 | 2009 | 441 | 0.060 |
Why?
|
Diet Therapy | 1 | 2005 | 151 | 0.060 |
Why?
|
Sympathetic Nervous System | 1 | 1987 | 518 | 0.060 |
Why?
|
Enoxaparin | 1 | 2006 | 391 | 0.060 |
Why?
|
Work Schedule Tolerance | 2 | 2004 | 551 | 0.060 |
Why?
|
Internationality | 2 | 2021 | 1001 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4176 | 0.050 |
Why?
|
United States | 9 | 2022 | 72340 | 0.050 |
Why?
|
Antithrombins | 1 | 2006 | 294 | 0.050 |
Why?
|
Blood Viscosity | 1 | 2003 | 124 | 0.050 |
Why?
|
Heart Arrest | 2 | 2010 | 1514 | 0.050 |
Why?
|
Thromboembolism | 1 | 2009 | 995 | 0.050 |
Why?
|
Diabetes Complications | 2 | 1989 | 1315 | 0.050 |
Why?
|
Environmental Monitoring | 2 | 2010 | 1460 | 0.050 |
Why?
|
Angiotensins | 1 | 2023 | 143 | 0.050 |
Why?
|
Risk | 6 | 2008 | 9610 | 0.050 |
Why?
|
Age Factors | 9 | 2020 | 18399 | 0.050 |
Why?
|
Chronic Disease | 4 | 2006 | 9319 | 0.050 |
Why?
|
Hemorrhage | 2 | 2009 | 3424 | 0.050 |
Why?
|
Body Mass Index | 2 | 2019 | 12953 | 0.050 |
Why?
|
Postoperative Hemorrhage | 1 | 2006 | 415 | 0.050 |
Why?
|
Dust | 1 | 2005 | 487 | 0.050 |
Why?
|
Necrosis | 2 | 2018 | 1611 | 0.050 |
Why?
|
Organotechnetium Compounds | 1 | 2002 | 129 | 0.050 |
Why?
|
Iatrogenic Disease | 1 | 2005 | 540 | 0.050 |
Why?
|
Rabbits | 1 | 2008 | 4772 | 0.050 |
Why?
|
Lovastatin | 1 | 2002 | 115 | 0.050 |
Why?
|
Verapamil | 2 | 2000 | 242 | 0.050 |
Why?
|
Carbon Monoxide | 1 | 2005 | 547 | 0.050 |
Why?
|
Risk Management | 1 | 2005 | 558 | 0.050 |
Why?
|
Boston | 6 | 2017 | 9327 | 0.050 |
Why?
|
Hostility | 1 | 2022 | 183 | 0.050 |
Why?
|
Renin | 1 | 2023 | 641 | 0.050 |
Why?
|
Acute Disease | 4 | 2006 | 7237 | 0.050 |
Why?
|
Attention | 2 | 2004 | 2396 | 0.050 |
Why?
|
Organophosphorus Compounds | 1 | 2002 | 206 | 0.050 |
Why?
|
Systole | 2 | 2004 | 936 | 0.050 |
Why?
|
Chronotherapy | 1 | 2000 | 11 | 0.050 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 322 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 2 | 1997 | 1164 | 0.040 |
Why?
|
Clinical Protocols | 2 | 2019 | 1440 | 0.040 |
Why?
|
Defibrillators, Implantable | 1 | 2009 | 1490 | 0.040 |
Why?
|
Practice Guidelines as Topic | 4 | 2010 | 7391 | 0.040 |
Why?
|
Radionuclide Ventriculography | 1 | 1999 | 40 | 0.040 |
Why?
|
Thallium Radioisotopes | 1 | 1999 | 138 | 0.040 |
Why?
|
Anger | 1 | 2022 | 406 | 0.040 |
Why?
|
Body Surface Area | 1 | 2020 | 197 | 0.040 |
Why?
|
Phenotype | 2 | 2017 | 16592 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2000 | 385 | 0.040 |
Why?
|
MicroRNAs | 1 | 2015 | 3816 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2023 | 737 | 0.040 |
Why?
|
Longitudinal Studies | 4 | 2019 | 14608 | 0.040 |
Why?
|
Aldosterone | 1 | 2023 | 870 | 0.040 |
Why?
|
Biology | 1 | 2020 | 290 | 0.040 |
Why?
|
Regeneration | 1 | 2007 | 1512 | 0.040 |
Why?
|
Survival Rate | 6 | 2010 | 12723 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2005 | 1496 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2010 | 3359 | 0.040 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2007 | 1081 | 0.040 |
Why?
|
Multicenter Studies as Topic | 5 | 2006 | 1702 | 0.040 |
Why?
|
Intensive Care Units | 3 | 2005 | 3744 | 0.040 |
Why?
|
Counseling | 1 | 2005 | 1547 | 0.040 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 5127 | 0.040 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 1068 | 0.040 |
Why?
|
Autonomic Nervous System Diseases | 2 | 2010 | 269 | 0.040 |
Why?
|
Anxiety | 2 | 2009 | 4573 | 0.030 |
Why?
|
Heart Diseases | 2 | 2006 | 2781 | 0.030 |
Why?
|
Absorbable Implants | 1 | 2019 | 338 | 0.030 |
Why?
|
Heart Failure | 7 | 2008 | 11671 | 0.030 |
Why?
|
Cardiomyopathies | 1 | 2008 | 1964 | 0.030 |
Why?
|
Occupational Exposure | 1 | 2006 | 1813 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2020 | 983 | 0.030 |
Why?
|
Catecholamines | 1 | 1996 | 386 | 0.030 |
Why?
|
HLA Antigens | 1 | 1981 | 1328 | 0.030 |
Why?
|
Oscillometry | 1 | 2016 | 150 | 0.030 |
Why?
|
Problem Solving | 1 | 1998 | 443 | 0.030 |
Why?
|
Cholestyramine Resin | 1 | 1994 | 25 | 0.030 |
Why?
|
Gemfibrozil | 1 | 1994 | 30 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2020 | 14417 | 0.030 |
Why?
|
Combined Modality Therapy | 4 | 1996 | 8527 | 0.030 |
Why?
|
Oxygen | 1 | 2006 | 4227 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2330 | 0.030 |
Why?
|
Life Style | 1 | 2006 | 3917 | 0.030 |
Why?
|
Sex Characteristics | 2 | 2020 | 2639 | 0.030 |
Why?
|
Internship and Residency | 2 | 2004 | 5882 | 0.030 |
Why?
|
Incidence | 3 | 2009 | 21355 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2016 | 1379 | 0.030 |
Why?
|
Peptides | 1 | 2006 | 4358 | 0.030 |
Why?
|
Heart Atria | 1 | 2020 | 1345 | 0.030 |
Why?
|
Niacin | 1 | 1994 | 118 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2006 | 5112 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2020 | 1188 | 0.030 |
Why?
|
Platelet Function Tests | 1 | 2015 | 271 | 0.030 |
Why?
|
Drug Administration Schedule | 3 | 2007 | 4853 | 0.030 |
Why?
|
Kidney | 2 | 2021 | 7048 | 0.030 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2003 | 1428 | 0.030 |
Why?
|
Thermodilution | 1 | 2013 | 50 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2003 | 2220 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 545 | 0.030 |
Why?
|
Protein Kinases | 1 | 2020 | 1608 | 0.030 |
Why?
|
Heart Murmurs | 2 | 1990 | 92 | 0.030 |
Why?
|
Shock, Cardiogenic | 2 | 1989 | 709 | 0.030 |
Why?
|
Humidity | 1 | 2014 | 205 | 0.030 |
Why?
|
Aorta | 1 | 2020 | 2041 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2003 | 5247 | 0.030 |
Why?
|
Adipose Tissue | 2 | 2022 | 3313 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2021 | 1745 | 0.020 |
Why?
|
Statistics as Topic | 2 | 1996 | 2358 | 0.020 |
Why?
|
Depression | 2 | 2009 | 8126 | 0.020 |
Why?
|
Consensus | 2 | 2017 | 3124 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14665 | 0.020 |
Why?
|
Comorbidity | 3 | 2016 | 10508 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 3415 | 0.020 |
Why?
|
Heart Ventricles | 4 | 2020 | 3807 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2002 | 1998 | 0.020 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2017 | 575 | 0.020 |
Why?
|
Seasons | 2 | 2014 | 1520 | 0.020 |
Why?
|
Fluorescein Angiography | 1 | 2017 | 1059 | 0.020 |
Why?
|
Clinical Enzyme Tests | 2 | 1988 | 113 | 0.020 |
Why?
|
Ambulatory Care | 3 | 1994 | 2775 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1638 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 3204 | 0.020 |
Why?
|
Drug Synergism | 1 | 2015 | 1757 | 0.020 |
Why?
|
Cost of Illness | 1 | 2021 | 1937 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2000 | 1809 | 0.020 |
Why?
|
Exercise | 3 | 2021 | 5890 | 0.020 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2010 | 112 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2021 | 11904 | 0.020 |
Why?
|
Sleep Deprivation | 3 | 2004 | 846 | 0.020 |
Why?
|
Obesity | 2 | 2015 | 12947 | 0.020 |
Why?
|
Manifest Anxiety Scale | 1 | 2009 | 7 | 0.020 |
Why?
|
Analysis of Variance | 4 | 1995 | 6228 | 0.020 |
Why?
|
Hospitalization | 8 | 2008 | 10721 | 0.020 |
Why?
|
False Negative Reactions | 3 | 1988 | 573 | 0.020 |
Why?
|
Heart Rupture | 1 | 1989 | 21 | 0.020 |
Why?
|
Heart Rupture, Post-Infarction | 1 | 1989 | 48 | 0.020 |
Why?
|
Algorithms | 3 | 2020 | 14033 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2002 | 3415 | 0.020 |
Why?
|
Sleep | 1 | 2004 | 4768 | 0.020 |
Why?
|
Evaluation Studies as Topic | 2 | 1988 | 1625 | 0.020 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2010 | 459 | 0.020 |
Why?
|
False Positive Reactions | 3 | 1988 | 957 | 0.020 |
Why?
|
Rheumatic Heart Disease | 1 | 1989 | 163 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 1988 | 372 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1853 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5205 | 0.020 |
Why?
|
Mitral Valve Prolapse | 1 | 1989 | 212 | 0.020 |
Why?
|
Signal Transduction | 2 | 2021 | 23447 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3578 | 0.020 |
Why?
|
Reference Values | 1 | 1994 | 4920 | 0.020 |
Why?
|
Pericarditis | 1 | 1989 | 135 | 0.020 |
Why?
|
Internal Medicine | 2 | 2004 | 1051 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2178 | 0.020 |
Why?
|
Temperature | 1 | 2014 | 2226 | 0.020 |
Why?
|
Missouri | 1 | 2007 | 115 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2007 | 6534 | 0.020 |
Why?
|
Age of Onset | 1 | 1994 | 3306 | 0.020 |
Why?
|
Coma | 1 | 2010 | 484 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 1999 | 12973 | 0.020 |
Why?
|
Recovery of Function | 1 | 2017 | 2979 | 0.020 |
Why?
|
Personality Inventory | 1 | 2009 | 1019 | 0.020 |
Why?
|
Bundle-Branch Block | 1 | 1988 | 276 | 0.020 |
Why?
|
Stroke Volume | 6 | 1991 | 5496 | 0.020 |
Why?
|
Evidence-Based Practice | 1 | 2010 | 495 | 0.020 |
Why?
|
Prevalence | 3 | 2018 | 15733 | 0.020 |
Why?
|
Death Certificates | 1 | 1987 | 167 | 0.020 |
Why?
|
Welding | 1 | 2006 | 89 | 0.020 |
Why?
|
Sulfur Dioxide | 1 | 2006 | 178 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2010 | 1171 | 0.020 |
Why?
|
Ohio | 1 | 2006 | 322 | 0.020 |
Why?
|
Fatty Acids, Omega-3 | 1 | 1995 | 1390 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5767 | 0.020 |
Why?
|
Digoxin | 1 | 1986 | 246 | 0.020 |
Why?
|
Educational Status | 1 | 1993 | 2522 | 0.020 |
Why?
|
Soot | 1 | 2007 | 221 | 0.020 |
Why?
|
Hirudins | 1 | 2006 | 179 | 0.020 |
Why?
|
Women | 1 | 1987 | 223 | 0.020 |
Why?
|
Tachycardia | 1 | 1987 | 600 | 0.020 |
Why?
|
Meteorological Concepts | 1 | 2004 | 30 | 0.020 |
Why?
|
Truth Disclosure | 1 | 2009 | 434 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2002 | 5440 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3905 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 931 | 0.020 |
Why?
|
Ventricular Fibrillation | 1 | 1987 | 537 | 0.010 |
Why?
|
Sinoatrial Node | 1 | 1985 | 99 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 1997 | 12463 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 883 | 0.010 |
Why?
|
Heart Block | 1 | 1986 | 386 | 0.010 |
Why?
|
Echocardiography | 1 | 2017 | 4989 | 0.010 |
Why?
|
Benzofurans | 1 | 1985 | 139 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10451 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3358 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8554 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2010 | 1301 | 0.010 |
Why?
|
Disability Evaluation | 1 | 1991 | 1836 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2927 | 0.010 |
Why?
|
Nitrogen Dioxide | 1 | 2006 | 522 | 0.010 |
Why?
|
Oxygen Consumption | 1 | 1990 | 1866 | 0.010 |
Why?
|
Amiodarone | 1 | 1985 | 217 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81539 | 0.010 |
Why?
|
Smoking | 3 | 2015 | 9053 | 0.010 |
Why?
|
Psychological Tests | 1 | 2005 | 640 | 0.010 |
Why?
|
Self-Assessment | 1 | 2005 | 397 | 0.010 |
Why?
|
Ozone | 1 | 2006 | 483 | 0.010 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2010 | 993 | 0.010 |
Why?
|
Benzazepines | 1 | 1985 | 310 | 0.010 |
Why?
|
Bronchodilator Agents | 1 | 2006 | 512 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2007 | 2217 | 0.010 |
Why?
|
Hypotension | 2 | 1986 | 879 | 0.010 |
Why?
|
Probability | 2 | 1987 | 2477 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1989 | 1474 | 0.010 |
Why?
|
Air Pollution, Indoor | 1 | 2009 | 901 | 0.010 |
Why?
|
Vasoconstriction | 1 | 2004 | 592 | 0.010 |
Why?
|
Melatonin | 1 | 2007 | 669 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2010 | 1886 | 0.010 |
Why?
|
Substance Withdrawal Syndrome | 1 | 1986 | 625 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 2006 | 1814 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6484 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 12990 | 0.010 |
Why?
|
Coronary Care Units | 1 | 1982 | 235 | 0.010 |
Why?
|
Mitral Valve Insufficiency | 1 | 1990 | 1400 | 0.010 |
Why?
|
Quality of Life | 1 | 2002 | 13367 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 2850 | 0.010 |
Why?
|
Remission Induction | 2 | 1995 | 2397 | 0.010 |
Why?
|
Twins | 1 | 1981 | 339 | 0.010 |
Why?
|
Medication Errors | 1 | 2005 | 783 | 0.010 |
Why?
|
Postoperative Complications | 2 | 2015 | 15633 | 0.010 |
Why?
|
Myocardium | 3 | 2003 | 4725 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2006 | 1161 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2005 | 2696 | 0.010 |
Why?
|
Polysomnography | 1 | 2004 | 1848 | 0.010 |
Why?
|
Exercise Therapy | 1 | 2004 | 929 | 0.010 |
Why?
|
Placebos | 2 | 1996 | 1667 | 0.010 |
Why?
|
Canada | 1 | 2002 | 2122 | 0.010 |
Why?
|
Troponin I | 1 | 2001 | 651 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2003 | 1787 | 0.010 |
Why?
|
Delayed-Action Preparations | 1 | 2000 | 962 | 0.010 |
Why?
|
Health Surveys | 1 | 2006 | 4061 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2003 | 1530 | 0.010 |
Why?
|
Clostridium perfringens | 1 | 1976 | 29 | 0.010 |
Why?
|
Phospholipases | 1 | 1976 | 75 | 0.010 |
Why?
|
Diphosphates | 2 | 1986 | 84 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 1986 | 1923 | 0.010 |
Why?
|
Insulin | 1 | 1989 | 6597 | 0.010 |
Why?
|
Isosorbide Dinitrate | 1 | 1994 | 34 | 0.010 |
Why?
|
Plant Oils | 1 | 1995 | 198 | 0.010 |
Why?
|
Information Systems | 1 | 1996 | 396 | 0.010 |
Why?
|
Adolescent | 3 | 2007 | 88326 | 0.010 |
Why?
|
Norepinephrine | 1 | 1996 | 897 | 0.010 |
Why?
|
Dietary Fats, Unsaturated | 1 | 1995 | 224 | 0.010 |
Why?
|
Massachusetts | 1 | 1987 | 8833 | 0.010 |
Why?
|
Epinephrine | 1 | 1996 | 792 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1981 | 4615 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2002 | 2650 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5493 | 0.010 |
Why?
|
Lipoproteins | 1 | 1995 | 881 | 0.010 |
Why?
|
Health Care Costs | 1 | 2003 | 3242 | 0.010 |
Why?
|
Clostridium Infections | 1 | 1976 | 558 | 0.000 |
Why?
|
Heart Septum | 1 | 1989 | 301 | 0.000 |
Why?
|
Survival Analysis | 1 | 2000 | 10090 | 0.000 |
Why?
|
Mass Screening | 1 | 2003 | 5429 | 0.000 |
Why?
|
Fatty Acids | 1 | 1995 | 1808 | 0.000 |
Why?
|
Heart Function Tests | 1 | 1987 | 318 | 0.000 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 1986 | 45 | 0.000 |
Why?
|
Technetium | 1 | 1986 | 317 | 0.000 |
Why?
|
Reoperation | 1 | 1995 | 4303 | 0.000 |
Why?
|
Bradycardia | 1 | 1986 | 299 | 0.000 |
Why?
|
Eating | 1 | 1990 | 1539 | 0.000 |
Why?
|
Regression Analysis | 1 | 1992 | 6345 | 0.000 |
Why?
|
Sepsis | 1 | 1976 | 2585 | 0.000 |
Why?
|
Patient Readmission | 1 | 1995 | 3271 | 0.000 |
Why?
|
Databases, Factual | 1 | 1996 | 7968 | 0.000 |
Why?
|
Drug Interactions | 1 | 1985 | 1416 | 0.000 |
Why?
|
Myocardial Contraction | 1 | 1985 | 1515 | 0.000 |
Why?
|
Pregnancy | 1 | 1981 | 29890 | 0.000 |
Why?
|
Kidney Diseases | 1 | 1988 | 2091 | 0.000 |
Why?
|
Chromatography, Thin Layer | 1 | 1976 | 213 | 0.000 |
Why?
|
Diglycerides | 1 | 1976 | 177 | 0.000 |
Why?
|
Anemia, Hemolytic | 1 | 1976 | 162 | 0.000 |
Why?
|
Patient Admission | 1 | 1982 | 1367 | 0.000 |
Why?
|
Anemia, Aplastic | 1 | 1976 | 230 | 0.000 |
Why?
|
Patient Compliance | 1 | 1984 | 2690 | 0.000 |
Why?
|
Length of Stay | 1 | 1982 | 6426 | 0.000 |
Why?
|